Azithromycin for Critical Asthma - Pediatrics

Part of paid clinical trials in St. Petersburg, Florida.

Sponsor
Johns Hopkins All Children's Hospital
Study ID
NCT06223828
Phase
PHASE2/PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • Critical Illness
  • Pediatric Asthma

Eligibility Criteria

Sex
ALL
Age
3 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • Azithromycin — DRUG
    10mg/kg/dose (max dose 500mg) once daily for 3 days

Study Details

The CR-AZI Study will assess the immunomodulatory effects of Azithromycin for pediatric Critical Asthma.

Key Dates

Start date
Apr 2, 2024
Status verified
Dec 2025
Primary completion
Jul 31, 2026
Completion
Dec 31, 2026

Study Design

Enrollment
100 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Azithromycin Intervention
    Participants in this arm will receive Azithromycin 10mg/kg/dose (max dose 500mg) once daily for 3 days.
  • No Intervention: Standard Care
    Participants will receive standard care without Azithromycin.

Primary Outcome Measure

Plasma Periostin Levels and Degree of Change (e.g., Slope) - Primary Physiologic Efficacy Endpoint [ Time Frame: 24 hours, 48 hours, and 72-hours following enrollment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins All Children's HospitalSt. PetersburgFlorida33701
Anthony A Sochet, MD
[email protected]
727-767-2912

Find similar trials in St. Petersburg, FL

By research site
Johns Hopkins All Children's Hospital· St. Petersburg, FL

Related Studies